Stoke Therapeutics (STOK) Long-Term Deferred Tax (2018 - 2021)
Stoke Therapeutics (STOK) posted quarterly Long-Term Deferred Tax of $66.0 million for Q4 2021, up 77.42% year-over-year from $37.2 million in Q4 2020, and up 77.42% quarter-over-quarter from $37.2 million in Q4 2020.
Stoke Therapeutics (STOK) Long-Term Deferred Tax (2018 - 2021) Analysis & Trends
Stoke Therapeutics' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $66.0 million for Q4 2021.
- In Q4 2021, Long-Term Deferred Tax rose 77.42% year-over-year to $66.0 million; the TTM figure through Dec 2021 stood at $66.0 million (up 77.42% YoY), while the FY2021 annual figure was $66.0 million, up 77.42% from the prior year.
- Long-Term Deferred Tax for Q4 2021 stood at $66.0 million, up from $37.2 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $66.0 million in Q4 2021, with the low at $7.6 million in Q4 2018.
- The 4-year median for Long-Term Deferred Tax is $27.6 million (2019), against an average of $32.2 million.
- The sharpest annual moves came in 2019 and 2021: Long-Term Deferred Tax jumped 135.53% in 2019, then jumped 77.42% in 2021.
- Stoke Therapeutics' Long-Term Deferred Tax stood at $7.6 million in 2018, then soared by 135.53% to $17.9 million in 2019, then jumped by 107.82% to $37.2 million in 2020, then surged by 77.42% to $66.0 million in 2021.
- Business Quant data shows STOK's Long-Term Deferred Tax at $66.0 million in Q4 2021, $37.2 million in Q4 2020, and $17.9 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 66.00 Mn |
| Dec 31, 2020 | 37.20 Mn |
| Dec 31, 2019 | 17.90 Mn |
| Dec 31, 2018 | 7.60 Mn |